OncoSec Medical Incorporated · OTC:ONCSQ
OncoSec Medical — Investor Presentation (July 2016)
33 slides from OncoSec Medical's investor presentation, July 2016
Slide 1: OncoSec: Arming the Immune System to Fight Cancer
ON C OS E C TM ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS0
Slide 2: Forward Looking Statements
Forward Looking Statements Our commentary and responses to your questions may contain forward looking statements, as described in the Private Securities Litigation Reform Act of 1995. These include comments concerning clinical trials and product development programs, evaluation of potential opportun
Slide 3: OncoSec Corporate Overview
OncoSec Corporate Overview Advancing a Leading Portfolio of Gene Therapies for Cancer Gene Therapy Product Portfolio ¡ Intratumoral DNA-based immuno-oncology therapies ¡ Platform focused on reversing the immuno-suppressive tumor microenvironment ¡ Capable of delivering multiple immune molecules in a
Slide 4: Core Clinical Pipeline
Core Clinical Pipeline Aligned to Pursue Combination Approaches PRECLINICAL PHASE I PHASE II PHASE III Metastatic Melanoma Melanoma Combination Study IL-12 + Anti- PD-1 (KEYTRUDA®) Triple Negative Breast Cancer Solid Tumors 3 Orange = Monotherapy with IL-12 | Green = Combination Therapy | Blue = New
Slide 5: Core Technology: ImmunoPulse
Core Technology: ImmunoPulse™ Overcoming Tumor Immune Tolerance via Intratumoral Immunotherapy ¡ Trains immune system to target and attack cancer ¡ Local delivery targets tumors directly triggering a systemic (abscopal) response with limited systemic exposure ¡ Ability to deliver a wide-variety of p
Slide 6: Anti-PD-1 Non-Responders Constitute Majority of Patients
Anti-PD-1 Non-Responders Constitute Majority of Patients ¡ Anti-PD-1 can re-invigorate Anti-PD-1/PD-L1 mAB Tumor Type Non-Response ‘exhausted’ T cells, allowing them to attack and kill Melanoma ~ 60 – 80% immunogenic tumor cells Triple Negative ¡ Majority of patients lack sufficient ~70 – 82% 1 Brea
Slide 7: The Unmet Medical Need of Low-TIL Tumors
The Unmet Medical Need of Low-TIL Tumors Driving Immunogenicity to Overcome Anti-PD-1 Non-Response PD-1 PD-L1 PD-1 x PD-L1 Response ImmunoPulse™ IL-12 Progress Adapted from Tumeh-PC, Nature. 2014 Nov 26; 515(7528): PD-1 blockade induces 6 responses by inhibiting adaptive immune resistance
Slide 8: Rationale for Combination of ImmunoPulse IL-12 and Anti-PD-1 Blockade
Rationale for Combination of ImmunoPulseTM IL- 12 and Anti-PD-1 Blockade Hypothesis: Activation of the PD-1 checkpoint in distant, untreated tumors blunts the effectiveness of TILs generated by ImmunoPulseTM IL-12 PD-1 Blockade 7
Slide 9: Preclinical Proof-of-Principle
PRECLINICAL PROOF-OF-PRINCIPLE Local Intratumoral Therapy Leads to Increased TILs & Tumor-Specific Systemic Response 8
Slide 10: ImmunoPulse IL-12
ImmunoPulse™ IL-12 Local Delivery Triggers Systemic Anti-Tumor Immune Response ¡ Uses DNA-encoded interleukin-12 ¡ Delivered directly to tumor in vivo; (IL-12), a potent pro-inflammatory stimulates local immune response, cytokine and subsequently, systemic effect ① Injection of ② Intratumoral ③ IL-1
Slide 11: Distant Tumor Effect in B16 Melanoma Tumor Model
Distant Tumor Effect in B16 Melanoma Tumor Model Primary Tumor Response Contralateral Tumor Response A. B. ¡ ImmunoPulse™ IL-12 leads to regression of treated tumor ¡ ImmunoPulse™ IL-12 significantly reduces growth of untreated (contralateral) tumors ¡ ImmunoPulse™ IL-12 monotherapy è range of ~10-4
Slide 12: Tumor-Specific Neo-Antigen Response in B16-OVA Melanoma
Tumor-Specific Neo-Antigen Response Following Treatment in B16-OVA Melanoma A. Untreated B. IT-pIL12-EP C. % SIINFEKL tetramer+ SIINFEKL+ tetramer SIINFEKL+ tetramer Untreated IT-pIL12-EP CD44 CD44 ¡ The untreated B16-OVA mice failed to demonstrate a significant expansion of SIINFEKL+ CD8 T cells ¡
Slide 13: Clinical Proof-of-Concept
CLINICAL PROOF-OF-CONCEPT ImmunoPulse™ IL-12 Effective in Multiple Tumor Types Data Provides Rationale for Combination with Checkpoint Inhibitors 12
Slide 14: Phase II Metastatic Melanoma Data
Phase II Metastatic Melanoma Data Drives Local and Systemic Anti-Cancer Immune Response Best Overall Complete Patients with regression Disease Response Rate* Response Rate* of at least one non- Control treated lesion Rate* COMPLETE RESPONSE: Pre-Treatment Treated Scalp Lesions - Day 180 13
Slide 15: Phase II Merkel Cell Carcinoma Data
Phase II Merkel Cell Carcinoma Data ImmunoPulse™ IL-12 Can Drive Antigen-Specific CD8+ T Cells in Patients 3 months Immediately Negative Control Pre-treatment Pre-treatment Pre-treatment MCC-specific tetramer +2 weeks +8 months +10 months Distant Post-treatment Lesion CD8 14
Slide 16: ImmunoPulse IL-12 Can Increase TILs
ImmunoPulse™ IL-12 Can Increase TILs Critical Priming of Tumors for Response to Checkpoint Inhibitors ImmunoPulse™ IL-12 can convert T cell poor tumors to T cell rich tumors, which are more likely to respond to anti-PD-1 therapies Metastatic Melanoma Merkel Cell Carcinoma Pre-ImmunoPulse IL-12 Post-
Slide 17: Long-Term Follow-Up Clinical Melanoma Data: Study Schema
Long-Term Follow-Up Clinical Melanoma Data: Study Schema Prospective study of IT-pIL12-EP monotherapy in advanced melanoma IT-pIL12-EP Schedule 1-5-8 Retrospective analysis of IT-pIL12-EP- (N=18) treated patients who received subsequent PD-1/PDL1 inhibitors Repeat cycle every 90 days Day Day Day D/C
Slide 18: ImmunoPulse IL-12 May Enhance Response Rates to PD-1/PD-L1 Blockade
ImmunoPulse™ IL-12 May Enhance Response Rates to PD-1/PD-L1 Blockade ¡ Patients who received ImmunoPulse™ IL-12 and later went on to receive a PD-1/PD-L1 inhibitor demonstrated a high response rate (n=14; 64% BORR) and those who did not have an intervening therapy had a BORR of 75% (n=8) ¡ ImmunoPul
Slide 19: Building a Unique Immuno-Oncology Platform
BUILDING A UNIQUE IMMUNO-ONCOLOGY PLATFORM 18
Slide 20: OncoSec's Platform Solution
OncoSec’s Platform Solution Addressing the Problem of Tumor-Induced Immune Subversion ④ Trafficking and T- ⑤ Infiltration of T-cell cell to Tumors into Tumors CX3CL1 CXCL9 LFA1/ICAM1 CXCL10 CCL5 VEGF Endothelin B receptor ③ Priming and ⑥ Recognition of T- Activation cell into Tumors CD28 CD137 T-cel
Slide 21: A Market Primed for Significant Growth
A Market Primed for Significant Growth Addressing a Great Unmet Medical Need in Oncology Percentage of Projected market value of Patients with solid tumors cancer checkpoint therapies, such that will not respond to immunotherapy as anti-PD-1 treatments checkpoint therapies treatment regimens alone e
Slide 22: Core Clinical Pipeline
Core Clinical Pipeline Aligned to Pursue Combination Approaches PRECLINICAL PHASE I PHASE II PHASE III Metastatic Melanoma Melanoma Combination Study IL-12 + Anti- PD-1 (KEYTRUDA®) Triple Negative Breast Cancer Solid Tumors 21 Orange = Monotherapy with IL-12 | Green = Combination Therapy | Blue = Ne
Slide 23: Phase II Metastatic Melanoma Combination Study
Phase II Metastatic Melanoma Combination Study RATIONALE COLLABORATORS ¡ Tumors need TILs for patients to respond to anti-PD-1 therapies ¡ Priming tumor microenvironment with IL-12 and promoting T-cell recruitment may enhance response to KEYTRUDA (pembrolizumab) OBJECTIVES ¡ Assess safety and effica
Slide 24: Pilot Triple Negative Breast Cancer (TNBC) Study
Pilot Triple Negative Breast Cancer (TNBC) Study RATIONALE COLLABORATORS ¡ Response rates to checkpoint therapies in pre-selected TNBC population were only 18 to 33% in preliminary reports ¡ ImmunoPulse™ IL-12 may drive an inflammatory response in TNBC patients, increasing response to anti-PD-1 ther
Slide 25: Registration Path for ImmunoPulse IL-12 in Metastatic Melanoma
Registration Path for ImmunoPulse™ IL-12 in Metastatic Melanoma Potential for Fast-Track Designation and Accelerated Approval Fast-Track Designation: ¡ Designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need ¡ More frequent
Slide 26: Accelerated Approval Trial Design
Accelerated Approval Trial Design A multicenter Phase II Trial of intratumoral pIL-12 + electroporation in combination with pembrolizumab in patients with Stage III/IV melanoma who are refractory to pembrolizumab treatment ¡ Patients will be given pIL-12 every 6 weeks and pembrolizumab every 3 weeks
Slide 27: US Anti-PD-1 Market Opportunity and Projections
US Anti-PD-1 Market Opportunity and Projections The melanoma market in the US will increase from 2015-2022 ¡ In 2015, the melanoma market was $2.0B; by 2022, it will increase to $2.2B ¡ The growth is driven by increased incidence of melanoma, and the uptake of new anti-PD-1 drugs (Opdivo and Keytrud
Slide 28: Development Milestones
Development Milestones Key Value Drivers Over the Next 12 Months Clinical and regulatory objectives to initiate melanoma combination registration study Complete enrollment in the Phase II melanoma combo study and present preliminary clinical data Announce novel “multi-gene” combination ImmunoPulse™
Slide 29: OncoSec's Intellectual Property
OncoSec’s Intellectual Property Freedom to operate in critical areas (Licenses) ¡ ImmunoPulse™ IL-12 ¡ EP intratumoral delivery of immune stimulators Exploit existing IP ¡ Lifecycle management ¡ Data exclusivity ¡ Improvements ¡ Design patents Build broad new IP portfolio to address business needs ¡
Slide 30: OncoSec Management Team
OncoSec Management Team Experienced Leadership Team Punit Dhillon Chief Executive Officer Richard Slansky Joann Yao, MBA Chief Finance Officer VP, Market Development Robert H. Pierce, MD Tu Diep Chief Scientific Strategist VP, Operations Sheela Mohan-Peterson Sharron Gargrosky, PhD Chief Legal and C
Slide 31: Clinical and Scientific Advisors
Clinical and Scientific Advisors Dr. Daud is a longstanding member of OncoSec’s Melanoma Advisory Board and serves as Chief Clinical Strategist for OncoSec. He is a clinical professor of hematology/oncology at University of DEV SCI CLI MEL Adil Daud, MD California, San Francisco (UCSF), and Director
Slide 32: Financial Background
Financial Background Financial Runway to Achieve Critical Milestones NASDAQ ONCS Shares Outstanding 22.5M* Market Cap $30M Cash Equivalents $33M Cash Runway Q1 2018 Debt $0 *Includes 4.8M shares underlying the Series B pre-funded warrants, pursuant to the May 2016 registered direct financing 31
Slide 33: Thank You
THANK YOU NAS D AQ: ONCS SCAN THE CODE to download our complete Investor Overview www.OncoSec.com/ONCS-Investor-Package P 855-662-6732 OncoSec Headquarters: E investors@oncosec.com 5820 Nancy Ridge Drive W www.oncosec.com San Diego, CA 92121 32